The U.S. Preventive Services Task Force’s new guidelines to offer mammography from age 40 will save many lives.
The U.S. Preventive Services Task Force posted a draft recommendation statement on screening for cervical cancer.
The new breast cancer screening guidelines are not enough to save Black women
A breast surgical oncologist and breast radiologist weigh in
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Chief, Breast Surgical Oncology,
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Director, Breast Program, New York Presbyterian Brooklyn Methodist Hospital; Assistant professor of surgery, Weill Cornell Medicine
Vice chair, Diversity, Equity, and Inclusion,
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Department of Radiology, Associate professor of clinical radiology, Weill Cornell Medicine; Associate attending radiologist, New York-Presbyterian Hospital
Table of Contents
YOU MAY BE INTERESTED IN
AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.
COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.
Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.
